
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Category Reports Biotech
Tickers reports and analysis
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Biotech Radar: $APUS, $AVBP, $JUNS, $OSTX | October 6, 2026

$APUS and $AVBP lead opposite extremes as $JUNS begins Parkinson’s patient dosing and $OSTX reports survival data. The October 6 radar also covers $CNXU, $SCYX, $JAGX and $PCVX.
Anti-infectives: can $CRMD, $INVA, $SPRO and $SCYX turn approvals into durable cash flow?

CorMedix, Innoviva, Spero and SCYNEXIS connect infection prevention, hospital treatment and antifungal development. This analysis separates approved uses, launch plans, royalty rights, reimbursement, reported cash and conditional funding.
Myelofibrosis: $GERN, $INCY, $GSK, $KPTI and the next treatment frontier

Geron’s event-driven survival study, Incyte’s new ruxolitinib formulation, GSK’s anemia-oriented product and Karyopharm’s submitted combination application represent different ways to address myelofibrosis. Their trial populations, endpoint outcomes and funding conditions differ.
Cytokines: $IBRX, $XLO, $CTMX, $MDNAF and the control challenge

Engineered cytokines aim to make powerful immune signals more usable. ImmunityBio, Xilio, CytomX and Medicenna illustrate receptor design, conditional activation and the practical limits imposed by safety, manufacturing and funding.
Plasma: $ADMA, $GRFS, $CSLLY, $TAK and immune protection

ADMA, Grifols, CSL and Takeda compete across a demanding plasma supply chain. This analysis connects approved products and new formulations with manufacturing yield, distribution, working capital and the capital choices behind each equity.
Cell therapy: $IOVA, $LEGN, $GILD, $BMY and the economics of one patient, one batch

Iovance’s September 29 guidance increase puts cell-therapy execution back in focus. Legend, Gilead and Bristol Myers Squibb show why manufacturing capacity, patient access and accounting economics must be analyzed together.
What Could EADV 2026 Change for $NKTR, $ATTO, $INCY and $ARQT in Dermatology?

Nektar and Attovia bring the September 28 news trigger; Incyte and Arcutis supply the clinical and commercial context. A source-based comparison of what the next data can—and cannot—establish.
GLP-1: What Do the New Data Mean for $LLY, $NVO, $VKTX and $GPCR?

Lilly adds an indirect oral comparison as Viking closes a major financing. A source-led examination of four GLP-1 businesses, their evidence and next milestones.
Retina: Which of $KOD, $FDMT, $OCUL and $EYPT Leads the Race for Longer-Lasting Treatment?

Kodiak’s DAYBREAK results and 4DMT’s new pivotal DME program renew the focus on durable retinal therapies. A source-led comparison with Ocular and EyePoint examines what the data establish, where trial designs differ, and how funding changes the path to the next catalyst.
$CAPR | Capricor Therapeutics Total Catalyst Map

$CAPR Total Catalyst Map: Capricor Therapeutics FDA date, HOPE-3, WMS, cash, partnerships and 2026–2027 milestones, verified against primary sources.
A packed catalyst roadmap for these 5 hot biotech stocks

Five biotech stocks face a packed calendar of clinical data and FDA decisions. This map separates major evidence from presentations and study starts without inflating correlated events.
$DRTS — Total Catalyst Map

Alpha Tau Medical ($DRTS): 18 catalysts, 2026–2027 timelines, clinical readouts, FDA milestones, Tolmar, Japan and potential stock impact.
Getting medicines into the brain: shuttles, vectors and direct delivery | $DNLI, $QURE, $RHHBY, $VYGR

How $DNLI, $QURE, $RHHBY and $VYGR approach brain delivery: molecular shuttles, systemic vectors and direct infusion, from biomarkers to clinical benefit.
Inside the tumor: Alpha Tau and the delivery challenge | $ATNM, $CATX, $CNSY, $DRTS

Alpha Tau’s local radiation, clinical evidence and capital, alongside antibody, peptide and catheter approaches at $ATNM, $CATX, $CNSY and $DRTS.
Can removing a protein change treatment? $CCCC, $KYMR, $NRIX, $RIGL

How $CCCC, $KYMR, $NRIX and $RIGL connect protein degradation, molecular glues and PROTACs to clinical evidence, approved treatment and business economics.
What remains after the 2026 biotech collapses? $ALDX, $GOSS, $SION, $TENX

What remains for $ALDX, $GOSS, $SION and $TENX after 2026 setbacks? Clinical evidence, FDA pathways, cash, conditional financing and existing shareholder claims.
AI and new medicines: what turns a designed candidate into value? $ABCL, $ABSI, $RXRX, $SDGR

Follow $ABCL, $ABSI, $RXRX and $SDGR from AI-assisted discovery to experiments, human evidence and economic rights, with current programs and financing.
Time in biotech trials: why six months do not equal two years | $CADL, $IOVA, $KOD, $KYTX

Read clinical durability through $CADL, $IOVA, $KOD and $KYTX: follow-up, response duration, censoring, endpoints, safety and the financial cost of time.
Prostate cancer: where can four approaches improve care? $BNTX, $CADL, $JANX, $TLX

How $BNTX, $CADL, $JANX and $TLX address prostate cancer through local immunotherapy, T-cell engagers, ADCs, imaging and radiopharmaceutical development.
CAR-T in autoimmune disease: how long must benefit last? $ALLO, $CABA, $KYTX, $SANA

How durable benefit, freedom from chronic treatment, safety and capital shape autoimmune CAR-T development at $ALLO, $CABA, $KYTX and $SANA.



